HomeELVN • NASDAQ
add
Enliven Therapeutics Inc
Previous close
$17.82
Day range
$16.65 - $18.54
Year range
$13.30 - $30.01
Market cap
827.31M USD
Avg Volume
352.20K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 31.69M | 21.96% |
Net income | -28.54M | -25.53% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -31.62M | -22.04% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 289.56M | -9.66% |
Total assets | 302.57M | -11.73% |
Total liabilities | 14.27M | -43.05% |
Total equity | 288.30M | — |
Shares outstanding | 49.07M | — |
Price to book | 3.03 | — |
Return on assets | -25.22% | — |
Return on capital | -26.46% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -28.54M | -25.53% |
Cash from operations | -24.13M | -3.28% |
Cash from investing | 1.43M | 107.98% |
Cash from financing | 234.00K | -99.74% |
Net change in cash | -22.47M | -145.83% |
Free cash flow | -15.34M | 4.96% |
About
Founded
2016
Headquarters
Website
Employees
65
